Navigation Links
Pharmacyclics Announces Date of Fiscal Year End 2010 Financial Results and Conference Call and Presentation at Stifel Nicolaus Healthcare Conference
Date:9/9/2010

SUNNYVALE, Calif., Sept. 9 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of cancer and mediated diseases, today announced that it will report financial results for the fourth fiscal quarter and fiscal year ended June 30, 2010 after the NASDAQ Market closes on Monday, September 13, 2010.  The company will conduct a conference call and an audio webcast at 4:30 p.m. EDT on the same day.

Additionally, the company announced that Dr. Ahmed Hamdy, Chief Medical Officer, will provide a corporate and clinical overview at The Stifel Nicolaus Healthcare Conference.  The presentation will take place at the Four Seasons Hotel in Boston, Thursday, September 16, 2010 at 1:30 p.m. EDT.  A link to the live webcast of the presentation that can be found at: http://ir.pharmacyclics.com/events.cfm.Fiscal Year End Quarter 2010 Conference Call and Webcast DetailsDate: September 13, 2010Time: 4:30 PM EDTListen via Internet: http://ir.pharmacyclics.com/events.cfmToll-free: +1-877-407-8133International: +1-201-689-8040A webcast replay will be available on the Pharmacyclics website for 30 days.

About PharmacyclicsPharmacyclics® is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our mission and goal is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medial healthcare needs; and to identify promising product candidates based on exceptional scientific development expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate. We exist to make a difference for the better and these are important times to do just that.

Presently, Pharmacyclics has four product candidates in clinical development, a clinical development candidate in late stage pre clinical evaluation and several preclinical molecules in lead optimization. We are committed to high standards of ethics, scientific rigor, and operational efficiency as we move each of these programs to viable commercialization.

The Company is headquartered in Sunnyvale, California and is listed on NASDAQ under the symbol PCYC. To learn more about how Pharmacyclics advances science to improve human healthcare visit us at http://www.pharmacyclics.com.Contact:Ramses ErdtmannVice President of FinancePhone: 408-215-3325
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor
2. Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
3. Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
4. Pharmacyclics Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer
5. Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma
6. Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
7. Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.
8. Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkins Lymphoma
9. Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier
10. Pharmacyclics to Present at Merriman Curhan Fords Investor Summit 2009
11. Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... World Health Organization (WHO) expanded the Intended Use of the ... years, and above. Effective immediately, the PrePex device, manufactured by ... in the 14 priority countries in Southern and ... device to receive WHO Prequalification on 31 May 2013. ... The expanded use of PrePex for younger ages ...
(Date:5/23/2016)... 23, 2016 Gamida Cell, a ... of cancer and orphan genetic diseases, announced today it ... million from the Israel Innovation Authority (formerly the Office ... Economy and Industry. The mission of the Israel Innovation ... industries, including science and technology, while stimulating economic growth. ...
(Date:5/22/2016)... 2016 DS Biopharma (DS) ... anti-inflammatory compound DS102 in chronic obstructive pulmonary disease ... (NASH) patients. Recent DS preclinical data ... tissue and has bronchodilatory, anti-inflammatory and anti-fibrotic properties ... Company will publish further detail on these findings ...
Breaking Medicine Technology:
(Date:5/24/2016)... ... May 24, 2016 , ... Regenerative Medicine is being transformed ... stem cell therapy technology, protocols and patient results as have been achieved with ... a more accessible standard of care for patients worldwide. , As the Medical Advisory ...
(Date:5/24/2016)... ... May 24, 2016 , ... Backed by decades of experience, ... job, ensuring the best suited solution to meet regulatory requirements. Their professional staff ... lab in Istanbul. , Metroloji Okulu specializes in MadgeTech’s line of medical and ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... of Jonathan (Jon) Otterstatter to its board of directors. Otterstatter is ... leader in the development of technological innovations that lead to broad-based healthcare solutions. ...
(Date:5/24/2016)... ... May 24, 2016 , ... WaterAid launched the #perioddrama campaign to mark ... than 1 billion women around the world who do not have access to a toilet, ... the US about their dread of #perioddrama. The (sometimes hilarious) results help shine a light ...
(Date:5/24/2016)... ... May 24, 2016 , ... Aloria ... Services To Begin In June , Aloria Health, specializing in a re-imagined, client-oriented ... of Aloria Milwaukee, its first treatment facility for outpatient, day treatment and residential ...
Breaking Medicine News(10 mins):